41931-11-7

Upstream product

• 766-40-5 Mucochloric acid 
• 2312-23-4 m-chlorophenylhydrazine hydrochloride 
• 14763-20-3 3-chlorophenyl hydrazine 
• 87-56-9 mucochloric acid 

Downstream Products

• 1062369-24-7 C₁₉H₂₃ClN₄O₂ 
• 1062079-30-4 C₂₂H₂₉ClN₄O₄S 
• 1295575-97-1 C₂₄H₃₁ClN₄O₄ 
• 1062052-14-5 C₁₉H₂₂Cl₂N₄O₃ 
• 1415356-23-8 C₁₇H₁₂Cl₂N₂O₃ 
• 1062081-55-3 C₃₀H₃₀ClN₅O₄S 
• 1062082-97-6 C₂₆H₂₉ClN₄O₅S 
• 1062079-39-3 C₂₆H₂₉ClN₄O₅S 
• 1418006-62-8 C₂₆H₃₀ClN₅O₄ 
• 1417346-83-8 C₂₇H₃₀ClN₅O₄ 
• 1417346-96-3 C₂₈H₃₂ClN₅O₄ 
• 1062063-42-6 C₂₆H₂₈ClFN₄O₄S 
• 1417346-99-6 C₂₄H₃₁ClN₄O₅ 
• 1417347-00-2 C₂₄H₃₁ClN₄O₅ 

Relevant academic research and scientific papers

Biological evaluation and molecular docking studies of synthesized 5-substituted-2-chlorophenyl-4-chloro derivatives bearing pyridazinone moiety

Chemical modification of pyridazinone may lead to a potent therapeutic agent. In this study, biological properties of pyridazinone derivatives were evaluated by assessing their antimicrobial and in-vitro antioxidant activities. The reaction of a mucochloric acid and 3-chloro-phenylhydrazine hydrochloride led to the formation of 5-aryl-4-chloro-2-(3-chloro-phenyl)-2H-pyridazin-3-one derivatives 2(a-j). The target compounds were synthesized using nucleophilic substitution reaction. In-silico molecular docking studies of the synthesized compounds were carried out with the help of V-Life Science MDS 4.6 software using GRIP batch docking method to find out which derivative had a better docking. The newly synthesized compounds were characterized by FTIR,1HNMR,13C-NMR, MS, and elemental analysis. Antimicrobial and in-vitro antioxidant activity study of the novel synthesized compounds were screened. Compounds 2f and 2g showed good antimicrobial having an MIC 12.5 μg/mL against Staphylococcus aureus and Candida albicans and in-vitro antioxidant activities having an IC50 50.84. The experimental results were further supported by molecular docking analysis with better interaction patterns.

Design, synthesis and SAR analysis of novel potent and selective small molecule antagonists of NPBWR1 (GPR7)

Novel small molecule antagonists of NPBWR1 (GPR7) are herein reported. A high-throughput screening (HTS) of the Molecular Libraries-Small Molecule Repository library identified 5-chloro-4-(4-methoxyphenoxy)-2-(p-tolyl) pyridazin-3(2H)-one as a NPBWR1 hit antagonist with micromolar activity. Design, synthesis and structure-activity relationships study of the HTS-derived hit led to the identification of 5-chloro-2-(3,5-dimethylphenyl)-4-(4-methoxyphenoxy) pyridazin-3(2H)-one lead molecule with submicromolar antagonist activity at the target receptor and high selectivity against a panel of therapeutically relevant off-target proteins. This lead molecule may provide a pharmacological tool to clarify the molecular basis of the in vivo physiological function and therapeutic utility of NPBWR1 in diverse disease areas including inflammatory pain and eating disorders.

The optimization of pyridazinone series of glucan synthase inhibitors

A detailed structure-activity relationship study of a novel series of pyridazine-based small molecule glucan synthase inhibitors is described. The optimization of the PK profile of this series led to the discovery of compound 11g, which demonstrated in vivo potency ip in a lethal fungal infection model.

The synthesis and structure-activity relationship of pyridazinones as glucan synthase inhibitors

A structure-activity relationship study of the lead 5-[4-(benzylsulfonyl) piperazin-1-yl]-4-morpholino-2-phenyl-pyridazin-3(2H)-one 1 has resulted in the identification of 2-(3,5-difluorophenyl)-4-(3-fluorocyclopentyloxy)-5-[4- (isopropylsulfonyl)piperazin-1-yl]-pyridazin-3(2H)-one 11c as a β-1,3-glucan synthase inhibitor. Compound 11c exhibited significant efficacy in an in vivo mouse model of Candida glabrata infection.